Feature | April 04, 2014

Head-to-Head Study Reports Patient Comfort With Iodixanol, Iopamidol During Peripheral Arteriography

Iodixanol Iopamidol Contrast Media Peripheral Arteriography ACC.14 Clinical Stud

April 4, 2014 — GE Healthcare announced results from a new clinical study, which showed that patients receiving iodixanol (Visipaque) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving iopamidol (Isovue) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, iodixanol is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology’s 63rd Annual Scientific Session and Expo.

“Contrast-induced discomfort is commonly seen in patients undergoing peripheral arteriography,” said Thomas Todoran, M.D., lead author of the study and assistant professor of medicine, director of vascular medicine at Medical University of South Carolina. “Patient discomfort continues to be a challenge, primarily because of potential for body movement that may lead to image degradation. Results from this study showed that Visipaque use led to significantly less patient discomfort, heat or pain when compared to Isovue. The results of this comparative study suggest that Visipaque may be a preferable contrast agent for use in peripheral arteriography.”

While this study was not powered to detect a difference in image quality, the number of subjects with image quality rated as excellent was numerically greater in the Visipaque group (86.5%) versus the Isovue group (82.4%), but the difference was not statistically significant. Discomfort impacted image quality in 6.5% of Isovue subject images and in 3.2% of Visipaque subject images.

For more information: www.newsroom.gehealthcare.com

Related Content

News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 11, 2015
Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new interim analysis from a...
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Overlay Init